Cell Genesys is a South San Francisco-based biotechnology company. Since its inception, the company focused primarily on the development and commercialization of novel biological therapies for patients with cancer. In August 2008 and October 2008, the company terminated its two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer and subsequently placed on hold the further development of this program and implemented a substantial restructuring of business operations. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders.
On June 30th, 2009, BioSante announced entering into a definitive merger agreement with Cell Genesys (CEGE) in an all-stock transaction, with BioSante as the surviving company.